Japan M&A, Prescription for Growth
Japanese pharmaceutical companies—some of the most sophisticated and cash-rich in the world—are shopping abroad for targets to enrich their drug pipelines and counter the uncertain outlook for sales in Japan. But sellers are still insisting on hefty price-tags, despite slowing economic growth and depressed equity markets.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.